GTM-1207••••

Strong and specific immune stimulation of humans, mouse immune cells, and laboratory animals
High purity, endotoxin-free and sterile vials
Simple handling
Low price offering realized by large scale production

It's important to choose the right agonist for individual purpose.

Different classes of TLR9 agonists have been shown to have different effects on cells.

TLR9

A-Class TLR9 ligand

D35
 Induces high type I IFN production
 Low activity against B cells
 Useful for activation of pDCs, induction of IFN-α fromPBMCs, and activation of IFN-signal pathways

LigandB-Class TLR9 ligand

K3
 Stimulates B cells to activate TLR9-dependent NF-kBsignaling Low activity with respect to induction of IFN-α
 B-Class is useful for B cell activation, induction of IL -6 fromhuman PBMCs, and activation of the NF-kB signal pathway

high quality

endotoxin free*The picture is the product image.

Activity
Evaluated

low-cost
realization

Toll-like receptors (Toll-like receptors: TLRs) recognize
highly conserved structural motifs as part of the earlyinnate immune response to invading pathogens. TLR9
differentiates mammalian and bacterial DNA andinduces immune cell activation. Synthetic
oligonucleotides containing CpG motifs (CpG-ODN)
stimulate the immune system, promote the maturation
and activation of antigen-presenting cells, and promote
the induction of Th1 and inflammatory cytokines.
Aji Bio-Pharma provides high-quality TLR9 agonists
and controls to activate immune cells.

GTM-1207

Activity
Evaluation
Example 1 Cytokine Induction in Human PBMC

hIL-6250

2,500200

2,000
1,500

1,0002502001501001501005005050000

Human PBMC (1 x 106 cells) were assayed by ELISA for human
IFN-a and IL -6 concentrations in culture supernatants 24 h after
stimulation with 1 uM of each CpG. Bar graphs show mean ± SEM.

pg/mL

300

3,000

pg/mL

3,500

mIL-6(FL-DC)

mIFNa(FL-DC)

pg/mL

hIFNa

pg/mL

Example 2 Cytokine induction in mouse FL-DC

2,000
1,800
1,600
1,400
1,200
1,000
800
600
400
2000FL-DC from mouse bone marrow induced by FLT3L differentiation (2 x106 cells) was assayed by ELISA in mouse IFN-a and IL -6
concentrations in culture supernatants 24 h after stimulation with 1 uMof each CpG. Bar graphs show mean ± SEM.

This data is the result of a joint research project with Dr. Ken Ishii and Dr. Taiki Aoshi of the National Institute of Biomedical Innovation, Japan.
Reference
1. Ishii KJ, Gursel I, Gursel M, Klinman DM. Immunotherapeutic utility of constitutive and suppressive oligodeoxynucleotides. Curr Opin
Mol Ther. 2004 Apr; 6 (2): 166 -74.
2. Verthelyi D, Ishii KJ, Gursel M, Takeda F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct
CPG motifs. J Immunol. 2001 Feb 15; 2372 (4): 166 -7.

High quality with tightly controlled production and management ensured•

Filling in a pyrogen free, sterile environment

Production••

Filling

Cost reduction through mass production
Highly reproducible production

Catalog NumberClass

CN -65001

A

CN -65002
CN -65003

B

CN -65004

Product NameQC••

Various product certification
Ensure endotoxin no more than 0.5 EU/mg

Product Description

amount of supply

Price (excludingtax)

D 35 Et-Freepartial S-DNA

10 mg/vial × 140,000

D 35 (GC) Et-Free

For the D 35 control

10 mg/vial × 1

40,000K3 Et-Free

whole S-DNA

10 mg/vial × 1

40,000K3 (GC) Et-Free

for K3 control

10 mg/vial × 1

40,000*Et-Free: An abbreviation for endotoxin free (Guaranteed up to 0.5 EU/mg)
This product is a research reagent. It cannot be used for clinical purposes.
For life science research use only. Not for use in clinical procedures.
[manufacturing and distribution company]

Gene Design Co., Ltd.
567 0085 7- 29 Saito-Asagi, Ibaraki-shi, Osaka
TEL: 072-640-5180/FAX: 072-640-5181
E-mail: info@genedesign.co.jp
URL: http://www.genedesign.co.jp[sales agent]